De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. (3rd August 2021)

• Record Type: Journal Article
• Authors: Begna, Kebede H.; Kittur, Jaya; Yui, Jennifer; Gangat, Naseema; Patnaik, Mrinal M.; Al‐Kali, Aref; Elliott, Michelle A.; Hogan, William J.; Litzow, Mark R.; Hook, Christopher C.; Wolanskyj, Alexandra P.; Howard, Matthew T.; Hanson, Curtis A.; Ketterling, Rhett P.; Pardanani, Animesh D.; Tefferi, Ayalew
• Is Part Of: British journal of haematology. Volume 195:Number 3(2021)
• Page Start: 413
• Page End: 416
• Publication Date: 2021-08-03
• Subjects: leukaemia -- extramedullary -- survival -- prognosis -- chemotherapy; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.17742
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Institutional database search (1999–2020) for acute myeloid leukaemia (AML) identified 109 cases of myeloid sarcoma (MS), of which 19 were isolated and presented de novo . The latter displayed longer survival (median 78 months), compared to MS with synchronous intramedullary AML ( n = 32; median 16 months) and de novo AML without MS ( n = 729; median 22 months; P = 0·13). However, the difference in survival was no longer apparent after accounting for bone marrow cytogenetic risk status ( P = 0·67). Treatment‐induced MS tumour resolution was not affected by the presence of intramedullary disease ( P = 0·61). The current study clarifies the prognosis of de novo isolated MS, in the context of AML.